Apogenix’ new CD40 agonist HERA-CD40L significantly reduces tumor growth in prostate cancer model
- Preclinical data published in Frontiers in Immunology, a leading peer-reviewed journal
- Induction of pro-inflammatory state through functional switch from pro-tumor macrophages (TAMs) to anti-tumor macrophages
- Combination with radiotherapy provides significant benefit in prostate cancer models refractory to anti-PD-1 treatment
Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that new preclinical data were published in the leading peer-reviewed journal Frontiers in Immunology1. In the studies, Apogenix, in collaboration with the group from Professor Tim Illidge at the University of Manchester, UK, demonstrated the therapeutic benefits of the hexavalent CD40 agonist HERA-CD40L in models of prostate cancer refractory to anti-PD-1 therapies, both as monotherapy and in combination with radiotherapy.